[Elsevier] Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial |
|
This post will be closed automatically in 2026-10-23 23:22
Reward10points
|
100
Local government responses to procurement centralization: Evidence from Italy
100
Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation
10
Advancements in Janus two-dimensional materials: From basic theory to practical applications
10
Intelligent threat detection for MQTT protocol in resource constrained edge computing
100
North Carolina Macular Dystrophy: Long-term Follow-up of the Original Family
